Nido Biosciences’ lead drug hits a previously undrugged pocket as a way to potentially treat the rare neuromuscular disorder spinal and bulbar muscular atrophy. The startup’s tech platform screens neurons to find targets for new neurological disorder drugs.
NeuraLight just raised $25 million in its bid to create new, digital endpoints that can be used by clinicians and researchers to objectively measure neurological conditions with the ultimate goal - still several years away - to have the company's technology serve as the gold standard for neurological evaluation.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending on the progress of the research, Takeda could pay its new partner more than $900 million.
The company, Portland, Maine-based MedRhythms, is using sensors, software and music to build evidence-based neurologic interventions to help stroke patients improve their walking.
As opposed to taking a small molecule or even antibody approach to treating neurological disease, Neurona "is focused on unique compositions of cells that can be precisely targeted, integrated into damaged neural circuits, and provide activity-dependent regulation."